







A





B





C



D



Supplementary Figure 2


A**B**

A


IC50 (μM)	DAOY	UW228	ONS76	**IC50 (μM) cell-free assay
Tivantinib (no-ATP competitive)	0.19±0.06	0.36±0.04	0.34±0.07	0.355
Crizotinib (ATP competitive)	1.39±0.34	2.41±0.86	4.98±0.93	0.011* (cell-based assay)
Foretinib (ATP competitive)	0.78±0.04	0.87±0.55	1.96±0.51	0.0004
Tepotinib (ATP competitive)	5.88±4.20	N.D	N.D	0.004
AMG337 (ATP competitive)	N.D	N.D	N.D	0.001
JNJ38877605 (ATP competitive)	N.D	N.D	N.D	0.004
PF0421793 (ATP competitive)	N.D	N.D	N.D	0.0048 * (cell-based assay)

**Data were obtained from the MedChemExpress website (<https://www.medchemexpress.com/>) for all tested compounds.


B






C




D







Supplementary Figure 5

A




B





ONS76

Untreated




Tivantinib




Delayed mitosis

Foretinib



Mitotic slippage


Crizotinib




Mitotic slippage

DAOY

Untreated




Tivantinib




Mitotic death

Foretinib



Mitotic slippage

Crizotinib



Mitotic slippage